On Apr. 29, 2005, Amylin Pharmaceuticals and Eli Lilly announced the FDA had approved BYETTA(TM) (exenatide) injection as adjunctive therapy to improve blood sugar control in patients with type 2 diabetes who have not achieved adequate control on metformin and/or a sulfonylurea. BYETTA (pronounced bye-A-tuh), the trade name for exenatide, was the first in a new class of medicines known as incretin mimetics.